R347C Polymorphisms in ADRA1A Genes and Mirtazapine Treatment Response in Koreans with Major Depression

키워드

참고문헌 (31)

1. Alonso J, "Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project", Acta Psychiatr Scand Suppl, (420), pp.21~27 (2004)
2. Duffy A, "The implications of genetics studies of major mood disorders for clinical practice", J Clin Psychiatry, 61, pp.630~637 (2000)
3. Fava M, "The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression", J Clin Psychiatry, 64(Suppl 13), pp.26~29 (2003)
4. Fabbri C, "Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research", Am J Med Genet B Neuropsychiatr Genet, 162B, pp.487~520 (2013)
5. Stone EA, "Emerging evidence for a central epinephrine-innervated alpha 1-adrenergic system that regulates behavioral activation and is impaired in depression", Neuropsychopharmacology, 28, pp.1387~1399 (2003)
6. Huang K, "No association found between the promoter variants of ADRA1A and schizophrenia in the Chinese population", J Psychiatr Res, 42, pp.384~388 (2008)
7. Kasper S, "Efficacy of antidepressants in the treatment of severe depression:the place of mirtazapine", J Clin Psychopharmacol, 17(Suppl 1), pp.19S~28S (1997)
8. Kent JM, "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression", Lancet, 355, pp.911~918 (2000)
9. Rogoz Z, "Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors", J Physiol Pharmacol, 53, pp.105~116 (2002)
10. Rogóz Z, "Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats", J Physiol Pharmacol, 56, pp.661~671 (2005)
11. Kakui N, "Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor", Pharmacol Biochem Behav, 92, pp.393~398 (2009)
12. Freitas SR, "Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population", BMC Cardiovasc Disord, 8, pp.40~ (2008)
13. "National Center for Biotechnology Information"[URL]
14. Shibata K, "Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy", Br J Pharmacol, 118, pp.1403~1408 (1996)
15. Liu YR, "ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics", Pharmacogenomics J, 10, pp.30~39 (2010)
16. Klotsman M, "A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH", Pharmacogenomics J, 4, pp.251~259 (2004)
17. Clark DA, "Expression of the alpha1A-adrenergic receptor in schizophrenia", Neurosci Lett, 401, pp.248~251 (2006)
18. Elia J, "Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A", Psychiatr Genet, 19, pp.134~141 (2009)
19. Vargas-Alarcón G, "Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains", Arthritis Rheum, 60, pp.2169~2173 (2009)
20. Burcescu I, "Association study of the adrenergic receptors and childhood-onset mood disorders in Hungarian families", Am J Med Genet B Neuropsychiatr Genet, 141B, pp.227~233 (2006)
21. Lario S, "MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene", Clin Genet, 51, pp.129~130 (1997)
22. Small KM, "Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression", Proc Natl Acad Sci U S A, 103, pp.5472~5477 (2006)
23. Yoshida K, "Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.1279~1283 (2002)
24. Shorter D, "Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation", Eur Neuropsychopharmacol, 23, pp.1401~1407 (2013)
25. Keller MB, "Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond", JAMA, 289, pp.3152~3160 (2003)
26. Clark DA, "Polymorphisms in the promoter region of the alpha1Aadrenoceptor gene are associated with schizophrenia", schizoaffective disorder in a Spanish isolate population, 2005, pp.58, 435~439
27. Arnsten AF, "Adrenergic targets for the treatment of cognitive deficits in schizophrenia", Psychopharmacology (Berl), 174, pp.25~31 (2004)
28. Fallin MD, "Linkage and association on 8p21.2-p21.1 in schizophrenia", Am J Med Genet B Neuropsychiatr Genet, 156, pp.188~197 (2011)
29. Birnbaum SG, "Protein kinase C overactivity impairs prefrontal cortical regulation of working memory", Science, 306, pp.882~884 (2004)
30. Siris SG, "Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents", Am J Psychiatry, 157, pp.1379~1389 (2000)
31. de Figueiredo JM, "Depression and demoralization: phenomenologic differences and research perspectives", Compr Psychiatry, 34, pp.308~311 (1993)

관련 논문AI추천